New drug combo aims to shrink tumors before surgery in Hard-to-Treat rectal cancer
NCT ID NCT07160647
Summary
This study is testing whether giving two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help shrink or eliminate tumors in patients with a specific type of locally advanced rectal cancer. The main goal is to see if the treatment leads to a 'pathologic complete response,' meaning no cancer cells are found in the surgical specimen. Researchers will also closely monitor side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR/MSI-H-TYPE RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, 310016, China
Conditions
Explore the condition pages connected to this study.